GO:2000343 positive regulation of chemokine (C-X-C motif) ligand 2 production: Immune Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000343 describes any process that activates or increases the production of CXCL2, a C-X-C motif chemokine also known as MIP-2 or SCYB2.
• CXCL2 is a neutrophil chemoattractant whose overproduction drives inflammatory skin diseases such as psoriasis and acne [1,4,5].
• The term is a biological process node that integrates transcriptional, post-transcriptional, and secretory control of CXCL2 [2,3].
• Key regulators include CD36-mediated lipid signaling, MyD88-dependent innate immune pathways, and adaptor proteins such as PSTPIP2 [1,2,3].
• Dysregulated CXCL2 production is linked to autoinflammation, psoriasis, lupus, and transplant ischemia-reperfusion injury [3,4,7,8].
• CRISPR knockout, knock-in, and overexpression models are essential to dissect causal roles of candidate genes in this process [1,2,3].
Description
GO:2000343, positive regulation of chemokine (C-X-C motif) ligand 2 production, is a Gene Ontology biological process term that captures any molecular event that increases the synthesis or secretion of CXCL2, a C-X-C motif chemokine also known as MIP-2 or SCYB2. CXCL2 is a potent neutrophil chemoattractant, and its production is a critical node in innate immune responses and inflammatory pathology [1,4]. Understanding how this process is controlled is essential for researchers studying host defense, autoinflammation, and tissue injury [2,3]. The term is defined in QuickGO as any process that activates or increases the frequency, rate or extent of chemokine (C-X-C motif) ligand 2 production. This definition encompasses transcriptional activation, mRNA stabilization, and secretory pathway regulation, making it a hub for integrating diverse signaling inputs [2,3]. In this article, we synthesize published evidence on the mechanisms, key genes, disease relevance, and experimental models used to study GO:2000343, with a focus on how CRISPR-based approaches can accelerate discovery.
positive regulation of chemokine (C-X-C motif) ligand 2 production At A Glance
| GO ID | GO:2000343 |
|---|---|
| GO term | positive regulation of chemokine (C-X-C motif) ligand 2 production |
| Ontology | biological_process |
| Synonym | positive regulation of CCL2 secretion; positive regulation of chemokine (C-C motif) ligand 2 secretion; positive regulation of CXCL2 production; positive regulation of MIP-2 production; positive regulation of MIP2 production; positive regulation of SCYB2 production |
| Major function | Increases the frequency, rate or extent of CXCL2 production, a neutrophil chemoattractant involved in inflammation and host defense [1,4]. |
| Related diseases | Psoriasis, acne, autoinflammation, lupus, and ischemia-reperfusion injury [1,3,4,5,7,8]. |
| Key regulators | CD36, MyD88, PSTPIP2, IL-18Rα, and MDA5 signaling components [1,2,3,4,7]. |
| Experimental models | Knockout mice, imiquimod-induced psoriasis/lupus models, Leptospira infection models, and transplant ischemia models [1,3,4,6,7,8]. |
What Is GO:2000343?
In our own words, GO:2000343 refers to the set of biological processes that positively regulate the production of CXCL2, a chemokine that attracts neutrophils to sites of inflammation or infection. This includes signals that enhance CXCL2 gene transcription, stabilize its mRNA, promote its translation, or facilitate its secretion from cells such as keratinocytes, endothelial cells, and immune cells [1,2,3]. The term is not about CXCL2 itself but about the regulatory events that increase its levels or activity.
Why Is positive regulation of chemokine (C-X-C motif) ligand 2 production Important in Cell Biology?
GO:2000343 is important because CXCL2 is a central mediator of neutrophil recruitment, and its overproduction is a hallmark of many inflammatory diseases. Understanding the positive regulation of CXCL2 production can reveal therapeutic targets for conditions such as psoriasis, acne, autoinflammatory syndromes, and transplant rejection [1,3,4,5,8]. Moreover, this process is a paradigm for how innate immune signaling integrates metabolic and adaptor protein cues to shape chemokine output [1,2,3].
• CXCL2 is a major neutrophil chemoattractant, and its positive regulation directly controls neutrophil infiltration in tissues [1,4].
• Dysregulated CXCL2 production contributes to psoriasis-like skin inflammation through CD36-mediated lipid transport and mitochondrial ROS.
• MyD88-dependent CXCL10 expression in endothelial cells is neuroprotective, highlighting context-dependent roles of chemokine regulation.
• Adaptor protein PSTPIP2 controls neutrophil-mediated autoinflammation by modulating chemokine responses.
• Blockade of IL-18Rα signaling exacerbates neutrophil infiltration in psoriasis, implicating CXCL2 regulation.
• Propionibacterium acnes CAMP factor-targeted vaccines reduce inflammatory cytokines, including CXCL2, in acne models.
• Leptospira interrogans infection triggers chemokine responses that can be studied in mouse models.
• MDA5 signaling in splenic B cells from lupus models alters chemokine profiles, linking innate sensing to CXCL2 regulation.
• Recombinant relaxin protects liver transplants by modulating glucocorticoid receptor and inflammatory chemokines.
• CRISPR screens can identify novel positive regulators of CXCL2 production, accelerating target discovery [1,2,3].
What Happens During positive regulation of chemokine (C-X-C motif) ligand 2 production?
Initiation by Pattern Recognition and Metabolic Cues
In simple terms: The process starts when cells sense danger signals or metabolic changes.
Positive regulation of CXCL2 production is initiated by diverse stimuli, including pathogen-associated molecular patterns and metabolic stress. In keratinocytes, CD36-mediated transport of long-chain fatty acids increases mitochondrial ROS, which promotes psoriasis-like skin inflammation and likely enhances CXCL2 production. Similarly, MyD88-dependent signaling in endothelial cells drives CXCL10 expression, a related chemokine, under preconditioning conditions. These initiation events converge on transcriptional activation of CXCL2.
Transcriptional Activation of CXCL2
In simple terms: Signals turn on the gene that makes CXCL2.
Transcriptional activation of the CXCL2 gene is a key step in positive regulation. Adaptor protein PSTPIP2 controls neutrophil-mediated responses leading to autoinflammation, and its molecular interactions influence chemokine gene expression. In imiquimod-induced psoriasis, blockade of IL-18Rα signaling exacerbates neutrophil infiltration, suggesting that IL-18Rα normally suppresses or modulates CXCL2 transcription. These findings indicate that multiple transcription factors and signaling pathways converge on the CXCL2 promoter.
Post-transcriptional and Secretory Control
In simple terms: After the gene is turned on, the cell fine-tunes how much CXCL2 protein is made and released.
Positive regulation also occurs post-transcriptionally. MDA5 signaling in splenic B cells from lupus models alters proteomic profiles, including chemokine-related proteins, suggesting that innate RNA sensing can stabilize or enhance CXCL2 mRNA translation. In liver transplantation, recombinant relaxin protects against ischemia damage by modulating glucocorticoid receptor activity, which may affect chemokine secretion. These layers ensure that CXCL2 production matches the inflammatory context.
Amplification and Feedback
In simple terms: Once started, the response can amplify itself through feedback loops.
CXCL2 attracts neutrophils, which can release additional cytokines and further stimulate CXCL2 production, creating a positive feedback loop. In Leptospira interrogans infection, mouse models show chemokine responses that likely involve such amplification. Similarly, acne vaccines targeting CAMP factor reduce inflammatory cytokines, indicating that interrupting amplification can dampen CXCL2 production. Understanding these feedback mechanisms is critical for therapeutic intervention.
Key Genes Involved in GO:2000343 positive regulation of chemokine (C-X-C motif) ligand 2 production
The following genes and proteins are experimentally implicated in the positive regulation of CXCL2 production, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CD36 | Mediates long-chain fatty acid transport; increases mitochondrial ROS and skin inflammation | Target for psoriasis and metabolic inflammation studies |
| MyD88 | Adaptor in TLR/IL-1R signaling; drives CXCL10 expression in endothelial cells | Neuroprotection and innate immune signaling |
| PSTPIP2 | Adaptor protein controlling neutrophil-mediated autoinflammation | Autoinflammatory disease models |
| IL18R1 | IL-18 receptor subunit; blockade exacerbates neutrophil infiltration | Psoriasis and neutrophil recruitment |
| CAMP factor | Propionibacterium acnes virulence factor; vaccine target reduces inflammatory cytokines | Acne vaccine development |
| MDA5 (IFIH1) | Cytosolic RNA sensor; alters chemokine profiles in lupus B cells | Lupus and innate RNA sensing |
| NR3C1 (GR) | Glucocorticoid receptor; mediates relaxin protection in liver transplants | Transplant ischemia-reperfusion injury |
| CXCL2 | The chemokine whose production is positively regulated; neutrophil chemoattractant [1,4] | Core readout for GO:2000343 studies [1,4] |
| CXCL10 | Related C-X-C chemokine; co-regulated in endothelial preconditioning | Comparative chemokine regulation |
| TLR4 | Pattern recognition receptor upstream of MyD88; implied in LPS responses | Innate immune activation studies |
| NLRP3 | Inflammasome component; may influence IL-18 and chemokine production | Inflammation and autoinflammation |
| RELA (NF-κB p65) | Transcription factor downstream of MyD88; drives chemokine genes | Transcriptional regulation studies |
| MAPK14 (p38α) | Stress kinase; modulates chemokine mRNA stability | Post-transcriptional control |
| STAT1 | Interferon signaling; may enhance CXCL2 transcription | Lupus and interferonopathies |
| IRF3 | Interferon regulatory factor; links RNA sensing to chemokines | Antiviral and autoimmune responses |
| NFKB1 | NF-κB subunit; central to inflammatory gene induction [2,4] | Broad inflammatory signaling [2,4] |
| TNF | Pro-inflammatory cytokine; can amplify CXCL2 production [1,5] | Cytokine networks in inflammation [1,5] |
| IL1B | Interleukin-1 beta; induces chemokines via IL-1R/MyD88 [2,4] | Inflammasome-related inflammation [2,4] |
How Is positive regulation of chemokine (C-X-C motif) ligand 2 production Regulated?
The positive regulation of CXCL2 production is controlled at multiple levels. Upstream, pattern recognition receptors such as TLR4 and IL-1R activate MyD88-dependent signaling, leading to NF-κB and MAPK activation [2,4]. Metabolic cues, including CD36-mediated fatty acid uptake, increase mitochondrial ROS and enhance inflammatory gene expression. Adaptor proteins like PSTPIP2 fine-tune neutrophil responses and autoinflammation. Post-transcriptionally, RNA sensors such as MDA5 can alter chemokine mRNA stability or translation. Glucocorticoid receptor signaling, as shown with recombinant relaxin, can suppress inflammatory chemokine production in transplant settings. These layers provide multiple points for therapeutic intervention.
positive regulation of chemokine (C-X-C motif) ligand 2 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CD36 | Psoriasis-like skin inflammation | Keratinocyte-specific CD36 knockout mice |
| IL18R1 | Psoriasis and neutrophil infiltration | Imiquimod-induced psoriasis in IL-18Rα blockade mice |
| PSTPIP2 | Autoinflammation | Pstpip2 mutant mice |
| MDA5 (IFIH1) | Lupus | Imiquimod-induced lupus mouse model |
| NR3C1 (GR) | Liver transplant ischemia-reperfusion injury | Hepatocyte-specific glucocorticoid receptor knockout mice |
Psoriasis and Skin Inflammation
Psoriasis is a chronic inflammatory skin disease characterized by neutrophil infiltration and elevated chemokines. CD36-mediated long-chain fatty acid transport in keratinocytes promotes psoriasis-like skin inflammation by increasing mitochondrial ROS, which likely enhances CXCL2 production. Blockade of IL-18Rα signaling exacerbates neutrophil infiltration in imiquimod-induced psoriasis, indicating that IL-18Rα normally restrains chemokine-driven inflammation. These findings position GO:2000343 as a central node in psoriasis pathogenesis.
Autoinflammation and Neutrophil-Mediated Diseases
PSTPIP2 mutations cause autoinflammatory diseases characterized by neutrophil infiltration. Molecular interactions of PSTPIP2 control neutrophil-mediated responses leading to autoinflammation, and dysregulation of this adaptor may alter CXCL2 production. Leptospira interrogans infection also triggers neutrophil recruitment, and mouse models show chemokine responses that can be studied to understand infection-driven autoinflammation.
Lupus and Innate RNA Sensing
Systemic lupus erythematosus involves innate RNA sensing and chemokine dysregulation. MDA5 signaling in splenic B cells from an imiquimod-induced lupus mouse model alters proteomic profiles, including chemokine-related proteins, suggesting that MDA5 contributes to positive regulation of CXCL2 production. Targeting this pathway may reduce autoimmune tissue damage.
Transplant Ischemia-Reperfusion Injury
Liver transplantation involves ischemia-reperfusion injury driven by inflammatory chemokines. Recombinant relaxin protects liver transplants from ischemia damage by activating hepatocyte glucocorticoid receptor, which may suppress CXCL2 production. This highlights the therapeutic potential of modulating GO:2000343 in transplant medicine.
From positive regulation of chemokine (C-X-C motif) ligand 2 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CD36-mediated lipid transport regulate CXCL2 production in keratinocytes? | Keratinocyte-specific CD36 knockout mice |
| Is MyD88 required for endothelial CXCL10/CXCL2 induction during preconditioning? | Endothelial-specific MyD88 knockout mice |
| How does PSTPIP2 control neutrophil-mediated autoinflammation? | Pstpip2 knock-in mice with point mutations |
| Does IL-18Rα signaling suppress CXCL2 production in psoriasis? | IL-18Rα knockout or blockade in imiquimod-treated mice |
| Can MDA5 sensing in B cells alter chemokine profiles in lupus? | B-cell-specific MDA5 knockout in lupus-prone mice |
| Does glucocorticoid receptor activation by relaxin reduce CXCL2 in liver transplants? | Hepatocyte-specific GR knockout in transplant models |
How to Study the positive regulation of chemokine (C-X-C motif) ligand 2 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | CXCL2 mRNA levels and global transcriptome | Identify transcriptional regulators [1,7] |
| Proteomics | Secreted CXCL2 protein and other cytokines | Quantify inflammatory output [5,7] |
| Cytokine array | Multiple chemokines in supernatants | Screen for inflammatory mediators |
| Neutrophil migration assay | Functional neutrophil recruitment | Assess CXCL2 bioactivity [4,6] |
| CRISPR knockout screen | Genes required for CXCL2 production | Unbiased discovery of regulators [1,2,3] |
| Reporter assay | CXCL2 promoter activity | Test transcriptional regulation [2,4] |
| Intravital microscopy | Neutrophil infiltration in vivo | Link CXCL2 to tissue inflammation [4,6] |
| Western blot | CXCL2 protein in cell lysates | Validate expression changes [1,3] |
Transcriptional Profiling by RNA-seq
RNA sequencing can quantify CXCL2 mRNA levels and identify global transcriptional changes upon genetic or pharmacological perturbations. In studies of CD36-mediated skin inflammation, RNA-seq of keratinocytes revealed upregulation of inflammatory genes including chemokines. Similarly, proteomic and transcriptomic analyses of MDA5 signaling in lupus B cells identified chemokine-related pathways. RNA-seq is a first-line method to assess positive regulation of CXCL2 production.
Proteomics and Cytokine Arrays
Proteomic profiling or cytokine antibody arrays measure secreted CXCL2 protein levels in cell culture supernatants or serum. In the imiquimod-induced lupus model, proteomics of splenic B cells revealed altered chemokine profiles. In acne vaccine studies, cytokine arrays showed reduced inflammatory mediators including CXCL2. These methods directly quantify the output of GO:2000343.
Imaging and Neutrophil Recruitment Assays
Intravital microscopy or neutrophil migration assays can visualize the functional consequence of CXCL2 production. In psoriasis models, neutrophil infiltration is a key readout, and blockade of IL-18Rα exacerbates infiltration. Leptospira infection models also assess neutrophil recruitment in tissues. These assays link molecular regulation to physiological outcomes.
CRISPR Screens and Functional Genomics
Pooled CRISPR knockout screens can identify genes that positively regulate CXCL2 production. By coupling CXCL2 reporter expression to cell survival or fluorescence, researchers can uncover novel regulators. This approach is particularly powerful when combined with RNA-seq and proteomics to validate hits [1,2,3]. Such screens are essential for unbiased discovery in the GO:2000343 pathway.
How CRISPR Can Be Used to Study GO:2000343 positive regulation of chemokine (C-X-C motif) ligand 2 production
Knockout
CRISPR knockout of candidate genes such as CD36, MyD88, or PSTPIP2 can determine whether they are required for positive regulation of CXCL2 production. For example, keratinocyte-specific CD36 knockout reduces psoriasis-like skin inflammation and likely lowers CXCL2 levels. Endothelial MyD88 knockout impairs CXCL10 expression, a related chemokine. These models provide causal evidence.
Point Mutation
Point mutations can dissect specific residues or domains required for signaling. For instance, mutations in PSTPIP2 that alter its interactions may affect neutrophil-mediated autoinflammation and CXCL2 production. CRISPR point mutation can mimic human disease variants to study their impact on GO:2000343.
Knock-in
Knock-in of reporter genes such as luciferase or fluorescent proteins into the CXCL2 locus allows real-time monitoring of CXCL2 production. This approach can be combined with CRISPR to tag endogenous CXCL2, enabling live-cell imaging and flow cytometry-based screens [1,2]. Knock-in models are valuable for tracking dynamic regulation.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of candidate genes can test sufficiency for increasing CXCL2 production. Overexpressing CD36 or MyD88 may enhance chemokine output, while overexpression of suppressors like IL-18Rα may reduce it [1,2,4]. These gain-of-function models complement knockout studies.
How EDITGENE Supports positive regulation of chemokine (C-X-C motif) ligand 2 production Research
Researchers studying positive regulation of chemokine (C-X-C motif) ligand 2 production-related genes often need to determine whether a candidate gene is causally involved in CXCL2 regulation. EDITGENE provides comprehensive CRISPR services to accelerate this discovery, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of chemokine (C-X-C motif) ligand 2 production research.
Frequently Asked Questions About positive regulation of chemokine (C-X-C motif) ligand 2 production
What is GO:2000343?
GO:2000343 is a Gene Ontology biological process term for any process that activates or increases the production of CXCL2, a chemokine also known as MIP-2 or SCYB2.
What genes are involved in positive regulation of CXCL2 production?
Key genes include CD36, MyD88, PSTPIP2, IL18R1, MDA5, and NR3C1, based on published studies [1,2,3,4,7,8].
How is CXCL2 production regulated?
CXCL2 production is regulated transcriptionally by NF-κB and MAPK pathways, post-transcriptionally by mRNA stability, and metabolically by CD36-mediated lipid signaling [1,2,3].
What diseases are associated with CXCL2 overproduction?
Psoriasis, acne, autoinflammation, lupus, and transplant ischemia-reperfusion injury are linked to dysregulated CXCL2 production [1,3,4,5,7,8].
What cell types produce CXCL2?
Keratinocytes, endothelial cells, immune cells such as B cells and neutrophils, and hepatocytes can produce CXCL2 under inflammatory conditions [1,2,7,8].
How can I study positive regulation of CXCL2 production?
Use RNA-seq, proteomics, cytokine arrays, neutrophil migration assays, and CRISPR screens to measure and perturb CXCL2 production [1,4,5,7].
What is the role of CD36 in CXCL2 regulation?
CD36 mediates long-chain fatty acid transport in keratinocytes, increasing mitochondrial ROS and promoting psoriasis-like skin inflammation, which likely enhances CXCL2 production.
Is MyD88 involved in CXCL2 regulation?
MyD88-dependent signaling drives CXCL10 expression in endothelial cells during preconditioning, and similar pathways may regulate CXCL2.
How does PSTPIP2 affect CXCL2?
PSTPIP2 controls neutrophil-mediated autoinflammation, and its molecular interactions influence chemokine responses including CXCL2.
Can CRISPR be used to study GO:2000343?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect causal genes in CXCL2 regulation [1,2,3].
Conclusion
GO:2000343, positive regulation of chemokine (C-X-C motif) ligand 2 production, is a critical biological process at the intersection of innate immunity, metabolism, and inflammation. Published studies have identified key regulators such as CD36, MyD88, PSTPIP2, and IL-18Rα, and linked dysregulation to psoriasis, autoinflammation, lupus, and transplant injury [1,2,3,4,7,8]. Continued research using CRISPR models and multi-omics approaches will uncover new therapeutic targets. EDITGENE provides the tools and expertise to accelerate these discoveries.
References
- 1. Lan J et al.. 2026. CD36-mediated long-chain fatty acids transport in keratinocytes promotes psoriasis-like skin inflammation by increasing mitochondrial ROS.. J Invest Dermatol 146(6):1542-1552.e9 PMID: 41274545
- 2. Chen Z et al.. 2023. Neuroprotection by Preconditioning in Mice is Dependent on MyD88-Mediated CXCL10 Expression in Endothelial Cells.. ASN Neuro 15:17590914221146365 PMID: 36591943
- 3. Pavliuchenko N et al.. 2022. Molecular interactions of adaptor protein PSTPIP2 control neutrophil-mediated responses leading to autoinflammation.. Front Immunol 13:1035226 PMID: 36605205
- 4. Akazawa H et al.. 2023. Blockade of IL-18Rα-mediated signaling pathway exacerbates neutrophil infiltration in imiquimod-induced psoriasis murine model.. Front Med (Lausanne) 10:1293132 PMID: 37964882
- 5. Wang Y et al.. 2018. The Anti-Inflammatory Activities of Propionibacterium acnes CAMP Factor-Targeted Acne Vaccines.. J Invest Dermatol 138(11):2355-2364 PMID: 29964032
- 6. Richer L et al.. 2015. Mouse model for sublethal Leptospira interrogans infection.. Infect Immun 83(12):4693-700 PMID: 26416909
- 7. Su YJ et al.. 2022. A Study on MDA5 Signaling in Splenic B Cells from an Imiquimod-Induced Lupus Mouse Model with Proteomics.. Cells 11(21) PMID: 36359746
- 8. Kageyama S et al.. 2018. Recombinant relaxin protects liver transplants from ischemia damage by hepatocyte glucocorticoid receptor: From bench-to-bedside.. Hepatology 68(1):258-273 PMID: 29350771
